|
CA1339210C
(en)
|
1988-05-31 |
1997-08-05 |
John Lewicki |
Recombinant techniques for production of novel natriuretic and vasodilator peptides
|
|
US5225538A
(en)
|
1989-02-23 |
1993-07-06 |
Genentech, Inc. |
Lymphocyte homing receptor/immunoglobulin fusion proteins
|
|
US6406697B1
(en)
|
1989-02-23 |
2002-06-18 |
Genentech, Inc. |
Hybrid immunoglobulins
|
|
US6541610B1
(en)
|
1989-09-05 |
2003-04-01 |
Immunex Corporation |
Fusion proteins comprising tumor necrosis factor receptor
|
|
US5352770A
(en)
|
1990-04-20 |
1994-10-04 |
Hisayuki Matsuo |
Porcine derived novel physiologically active peptide
|
|
JP2930380B2
(ja)
|
1990-07-13 |
1999-08-03 |
壽之 松尾 |
ブタ由来新規生理活性ペプチド（ｃｎｐ―５３）
|
|
JP3026351B2
(ja)
|
1990-07-13 |
2000-03-27 |
壽之 松尾 |
ブタｃｎｐ遺伝子及び前駆体蛋白
|
|
JP2977159B2
(ja)
|
1990-09-07 |
1999-11-10 |
壽之 松尾 |
カエル由来新規生理活性ペプチド（カエルｃｎｐ）
|
|
JP2977158B2
(ja)
|
1990-09-07 |
1999-11-10 |
壽之 松尾 |
トリ由来新規生理活性ペプチド（ニワトリｃｎｐ）
|
|
JP3026352B2
(ja)
|
1990-09-11 |
2000-03-27 |
壽之 松尾 |
ラットＣＮＰｃＤＮＡ及び前駆体蛋白
|
|
JP3026354B2
(ja)
|
1990-09-27 |
2000-03-27 |
壽之 松尾 |
ヒトｃｎｐ遺伝子及び前駆体蛋白
|
|
JP2809533B2
(ja)
|
1991-01-31 |
1998-10-08 |
壽之 松尾 |
Ｃｎｐ類似体ペプチド
|
|
WO1992020371A1
(en)
|
1991-05-10 |
1992-11-26 |
Celtrix Pharmaceuticals, Inc. |
Targeted delivery of bone growth factors
|
|
WO1994020534A1
(en)
|
1993-03-03 |
1994-09-15 |
Mayo Foundation For Medical Education And Research |
Vasonatrin peptide and analogs thereof
|
|
WO1995005455A1
(en)
|
1993-08-13 |
1995-02-23 |
Rijksuniversiteit Te Groningen |
Pharmaceutical composition comprising phosphatase or a derivative thereof
|
|
US5665704A
(en)
|
1993-11-12 |
1997-09-09 |
Genentech, Inc. |
Receptor specific atrial natriuretic peptides
|
|
DK0728147T3
(da)
|
1993-11-12 |
2003-06-10 |
Genentech Inc |
Receptorspecifikke atrienatriuretiske peptider
|
|
US5846932A
(en)
|
1993-11-12 |
1998-12-08 |
Genentech, Inc. |
Receptor specific atrial natriuretic peptides
|
|
US6525022B1
(en)
|
1993-11-12 |
2003-02-25 |
Genentech, Inc. |
Receptor specific atrial natriuretic peptides
|
|
ES2188665T3
(es)
|
1994-06-02 |
2003-07-01 |
Forssmann Wolf Georg |
Procedimiento para la preparacion de fragmentos de cardiodilatina, fragmentos de cardiodilatina muy purificados y productos intermedios para su preparacion.
|
|
JPH0870875A
(ja)
|
1994-09-05 |
1996-03-19 |
Tosoh Corp |
組換えアルカリフォスファタ−ゼ融合タンパク質
|
|
US5863782A
(en)
|
1995-04-19 |
1999-01-26 |
Women's And Children's Hospital |
Synthetic mammalian sulphamidase and genetic sequences encoding same
|
|
US6028055A
(en)
|
1996-10-22 |
2000-02-22 |
Genetech, Inc. |
Receptor selective BNP
|
|
WO1998017690A1
(en)
|
1996-10-22 |
1998-04-30 |
Genentech, Inc. |
Receptor specific brain natriuretic peptide (bnp)
|
|
US6455495B1
(en)
|
1997-02-14 |
2002-09-24 |
The Salk Institute For Biological Studies |
Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
|
|
EP1950224A3
(en)
|
1998-03-09 |
2008-12-17 |
Zealand Pharma A/S |
Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
|
CA2245903A1
(en)
|
1998-09-28 |
2000-03-28 |
Mcgill University |
Use of pex in the treatment of metabolic bone diseases
|
|
CA2260376A1
(en)
|
1999-02-11 |
2000-08-11 |
Universite De Montreal |
New metalloproteases of the neprilysin family
|
|
CA2262056A1
(en)
|
1999-02-24 |
2000-08-24 |
Guy Boileau |
Composition, methods and reagents for the synthesis of a soluble form of human pex
|
|
AU2495200A
(en)
|
1999-03-08 |
2000-09-28 |
Genentech Inc. |
Compositions and methods for the treatment of tumor
|
|
AU772074B2
(en)
|
1999-04-28 |
2004-04-08 |
Vectramed, Inc. |
Enzymatically activated polymeric drug conjugates
|
|
EP2100901A1
(en)
|
1999-05-17 |
2009-09-16 |
ConjuChem Biotechnologies Inc. |
Modified Insulin and conjugates thereof
|
|
US6849714B1
(en)
|
1999-05-17 |
2005-02-01 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
|
WO2004011498A2
(en)
|
2002-07-31 |
2004-02-05 |
Conjuchem Inc. |
Long lasting natriuretic peptide derivatives
|
|
US20040266673A1
(en)
|
2002-07-31 |
2004-12-30 |
Peter Bakis |
Long lasting natriuretic peptide derivatives
|
|
US6887470B1
(en)
|
1999-09-10 |
2005-05-03 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
|
JP2000327583A
(ja)
|
1999-05-17 |
2000-11-28 |
Medei Sci Puraningu:Kk |
骨指向性ホルモン誘導体
|
|
DE19942230C2
(de)
|
1999-09-03 |
2003-09-25 |
Wolf-Georg Forssmann |
Verwendung natriuretischer Peptide als antibiotisch wirksame Subsanzen zur Behandlung von bakteriellen Infektionen
|
|
ES2284545T3
(es)
|
1999-11-16 |
2007-11-16 |
Genzyme Corporation |
Vectores y transgenes con elementos reguladores para la administracion de genes del higado.
|
|
US6407211B1
(en)
|
1999-12-17 |
2002-06-18 |
Mayo Foundation For Medical Education And Research |
Chimeric natriuretic peptides
|
|
WO2001044257A1
(en)
|
1999-12-17 |
2001-06-21 |
Ariad Pharmaceuticals, Inc. |
Proton pump inhibitors
|
|
JP4237375B2
(ja)
|
2000-03-31 |
2009-03-11 |
アスビオファーマ株式会社 |
虚血性疾患の処置又は予防に用いる医薬組成物
|
|
US20050142217A1
(en)
|
2000-04-26 |
2005-06-30 |
Adams Michael A. |
Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
|
|
US6946484B2
(en)
|
2000-04-26 |
2005-09-20 |
Cellegy Pharmaceuticals, Inc. |
Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
|
|
EP1502604A1
(en)
|
2000-04-26 |
2005-02-02 |
Cellegy Pharmaceuticals, Inc |
Use of nitric oxide mimetics in cancer treatment
|
|
US7678391B2
(en)
|
2000-04-26 |
2010-03-16 |
Queen's University At Kingston |
Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
|
|
US6830885B1
(en)
|
2000-08-18 |
2004-12-14 |
Phenogene Therapeutiques Inc. |
Nucleic acid molecule, method and kit for selecting a nucleic acid having a desired feature
|
|
CA2418461A1
(en)
|
2000-08-23 |
2002-02-28 |
Biomep Inc. |
Method and compositions for promoting osteogenesis
|
|
US6436386B1
(en)
|
2000-11-14 |
2002-08-20 |
Shearwater Corporation |
Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
|
|
DK1355942T3
(da)
|
2000-12-07 |
2008-11-17 |
Lilly Co Eli |
GLP-1-fusionsproteiner
|
|
JP2002178279A
(ja)
|
2000-12-12 |
2002-06-25 |
Ulvac Japan Ltd |
基板搬送方法
|
|
WO2002068579A2
(en)
|
2001-01-10 |
2002-09-06 |
Pe Corporation (Ny) |
Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
|
|
JP2002246704A
(ja)
|
2001-02-16 |
2002-08-30 |
Philips Japan Ltd |
電子装置及び回路装置
|
|
IL142118A0
(en)
|
2001-03-20 |
2002-03-10 |
Prochon Biotech Ltd |
Method and composition for treatment of skeletal dysplasias
|
|
US7888372B2
(en)
|
2001-03-23 |
2011-02-15 |
National Institutes Of Health (Nih) |
Compositions and methods for modulating bone mineral deposition
|
|
US20020183276A1
(en)
|
2001-03-23 |
2002-12-05 |
Burnham Institute |
Compositions and methods for modulating bone mineral deposition
|
|
EP1395293B1
(en)
|
2001-05-14 |
2009-07-22 |
Gbp Ip, Llc |
Lentiviral vectors encoding clotting factors for gene therapy
|
|
CA2652991A1
(en)
|
2001-07-16 |
2003-11-13 |
Caprotec Bioanalytics Gmbh |
Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
|
|
BRPI0203172B8
(pt)
|
2001-09-28 |
2021-05-25 |
Nakao Kazuwa |
composição farmacêutica para acondroplasia
|
|
US20050202442A1
(en)
|
2003-12-15 |
2005-09-15 |
Morris David W. |
Novel therapeutic targets in cancer
|
|
EP1458749B1
(en)
|
2001-12-20 |
2011-04-13 |
Enobia Pharma Inc. |
Bone polypeptide-1
|
|
US20080194481A1
(en)
|
2001-12-21 |
2008-08-14 |
Human Genome Sciences, Inc. |
Albumin Fusion Proteins
|
|
AU2002364586A1
(en)
|
2001-12-21 |
2003-07-30 |
Delta Biotechnology Limited |
Albumin fusion proteins
|
|
US20030158132A1
(en)
|
2002-01-22 |
2003-08-21 |
Genvec, Inc. |
Method for enhancing bone density or formation
|
|
AU2003208228A1
(en)
|
2002-03-06 |
2003-09-16 |
Cellegy Pharmaceuticals, Inc |
Formulations and methods of using nitric oxide mimetics in cancer treatment
|
|
AU2003214214A1
(en)
|
2002-03-18 |
2003-10-08 |
Scios Inc. |
Method for treating congestive heart failure
|
|
US20050113286A1
(en)
|
2002-03-18 |
2005-05-26 |
Schreiner George F. |
Methods for treating congestive heart failure
|
|
IL149562A0
(en)
|
2002-05-09 |
2002-11-10 |
Prochon Ltd |
Fgf variants and methods for use thereof
|
|
CA2433479A1
(en)
|
2002-07-22 |
2004-01-22 |
F. Hoffmann-La Roche Ag |
Conjugate of a tissue non-specific alkaline phosphatase and dextran, process for its production and use thereof
|
|
WO2004022579A2
(en)
|
2002-09-06 |
2004-03-18 |
University Of South Florida |
Cellular delivery of natriuretic peptides
|
|
EP1562990B1
(en)
|
2002-11-18 |
2010-07-21 |
Syn X Pharma, Inc. |
Polyclonal-monoclonal elisa assay for detecting n-terminus probnp
|
|
US7648962B2
(en)
|
2002-11-26 |
2010-01-19 |
Biocon Limited |
Natriuretic compounds, conjugates, and uses thereof
|
|
DE60331584D1
(de)
|
2002-11-26 |
2010-04-15 |
Biocon Ltd |
Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen
|
|
US7105539B2
(en)
|
2002-12-03 |
2006-09-12 |
Enobia Pharma |
Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex
|
|
EP1583554A2
(en)
|
2003-01-13 |
2005-10-12 |
Gudrun Rappold-Hoerbrand |
Use of natriuretic peptides for the treatment of stature disorders related to the shox gene
|
|
US20060228710A1
(en)
|
2003-02-14 |
2006-10-12 |
Morris David W |
Novel therapeutic targets in cancer
|
|
US7488713B2
(en)
|
2004-03-18 |
2009-02-10 |
University Of South Florida |
Cancer treatment using C-type natriuretic peptides
|
|
JP2006527190A
(ja)
|
2003-04-17 |
2006-11-30 |
サイファージェン バイオシステムズ インコーポレイテッド |
ナトリウム利尿ペプチドに関連したポリペプチド、並びにこれらの同定および使用法
|
|
WO2005007809A2
(en)
|
2003-05-30 |
2005-01-27 |
Alexion Pharmaceuticals, Inc. |
Antibodies and fusion proteins that include engineered constant regions
|
|
CA2570398C
(en)
|
2003-06-17 |
2020-05-12 |
Otago Innovation Limited |
Assessment of skeletal growth using measurements of nt-cnp peptides
|
|
EP1638443B1
(en)
|
2003-06-20 |
2010-10-20 |
Mayo Foundation For Medical Education And Research |
Isoforms of brain natriuretic peptide
|
|
WO2005052593A1
(en)
|
2003-10-29 |
2005-06-09 |
The University Of Leicester |
Detection
|
|
US7431915B2
(en)
|
2003-10-31 |
2008-10-07 |
The Regents Of The University Of California |
Peptides whose uptake by cells is controllable
|
|
US8110665B2
(en)
|
2003-11-13 |
2012-02-07 |
Hanmi Holdings Co., Ltd. |
Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
|
|
BRPI0406606A
(pt)
|
2003-11-13 |
2005-12-06 |
Hanmi Pharm Ind Co Ltd |
Composição farmacêutica compreendendo uma região fc de imunoglobulina como um veìculo
|
|
US20060019890A1
(en)
|
2004-01-15 |
2006-01-26 |
Kapoun Ann M |
Method for treating cardiac remodeling following myocardial injury
|
|
US20080182299A1
(en)
|
2004-01-27 |
2008-07-31 |
Compugent Ltd. |
Novel brain natriuretic peptide variants and methods of use thereof
|
|
AU2005207886A1
(en)
|
2004-01-27 |
2005-08-11 |
Compugen Usa, Inc. |
Novel brain natriuretic peptide variants and methods of use thereof
|
|
ES2465141T3
(es)
|
2004-03-31 |
2014-06-05 |
Kazuwa Nakao |
Remedio o medicamento preventivo para la artritis
|
|
EP3620530A1
(en)
|
2004-03-31 |
2020-03-11 |
Kazuwa Nakao |
Composition for increasing body height
|
|
JP2005292718A
(ja)
|
2004-04-05 |
2005-10-20 |
Furukawa Electric Co Ltd:The |
光導波路、光導波路モジュールおよび光導波路の作成方法
|
|
HUE055861T2
(hu)
|
2004-04-21 |
2021-12-28 |
Alexion Pharma Inc |
Csontbejuttató konjugátumok és azok alkalmazási módszere fehérjék csonthoz kötéséhez
|
|
EP1758614A4
(en)
|
2004-05-04 |
2007-09-12 |
Univ Singapore |
Method for expressing sialylated glycoproteins in mammalian cells and cells thereof
|
|
CN1950095A
(zh)
|
2004-05-10 |
2007-04-18 |
诺瓦西股份有限公司 |
用活性的维生素d化合物预防动脉再狭窄
|
|
US7972593B2
(en)
|
2004-06-10 |
2011-07-05 |
Saint Louis University |
Delivery of therapeutic agents to the bone
|
|
US20070081984A1
(en)
|
2005-10-11 |
2007-04-12 |
Shunji Tomatsu |
Compositions and methods for treating hypophosphatasia
|
|
US7863238B2
(en)
|
2004-06-10 |
2011-01-04 |
Saint Louis University |
Proteins with an attached short peptide of acidic amino acids
|
|
US20070081986A1
(en)
|
2005-10-07 |
2007-04-12 |
Shunji Tomatsu |
Beta-glucuronidase with an attached short peptide of acidic amino acids
|
|
DE602005026014D1
(de)
|
2004-07-15 |
2011-03-03 |
Univ Queensland |
Proteinartige verbindungen und anwendungen davon
|
|
US20090142347A1
(en)
|
2004-09-29 |
2009-06-04 |
The Burnham Institute For Medical Research |
Tissue-Nonspecific Alkaline Phosphatase (TNAP): a Therapeutic Target for Arterial Calcification
|
|
JP2008521575A
(ja)
|
2004-12-01 |
2008-06-26 |
ジェンザイム・コーポレイション |
肝臓を標的とした遺伝物質の送達方法
|
|
WO2006110743A1
(en)
|
2005-04-07 |
2006-10-19 |
Cardiopep Pharma Gmbh |
Use of natriuretic peptide for treating heart failure
|
|
JP5255435B2
(ja)
|
2005-04-26 |
2013-08-07 |
メディミューン，エルエルシー |
ヒンジドメイン操作による抗体エフェクター機能の調節
|
|
US20070042957A1
(en)
|
2005-08-19 |
2007-02-22 |
Mayo Foundation For Medical Education And Research |
Type v phosphodiesterase inhibitors and natriuretic polypeptides
|
|
US7470668B2
(en)
|
2005-08-24 |
2008-12-30 |
Enobia Pharma Inc. |
Method of use of specific natriuretic peptide receptor c ligands, transgenic non-human mammals expressing specific natriuretic peptide receptor c antagonists and cells thereof
|
|
CA2621264A1
(en)
|
2005-09-06 |
2007-11-15 |
Zelos Therapeutics, Inc. |
Parathyroid hormone analogues and methods of use
|
|
US7803901B2
(en)
|
2005-09-16 |
2010-09-28 |
Mayo Foundation For Medical Education And Research |
Polypeptides with natriuresis activity
|
|
WO2007041645A2
(en)
|
2005-10-03 |
2007-04-12 |
Scios Inc. |
Oxidized human bnp
|
|
RU2316334C2
(ru)
|
2005-12-19 |
2008-02-10 |
Медитек Индастриз ЛЛС |
Способ активации утраченных двигательных функций, а также определения эффективности их восстановления при повреждении центральной нервной системы
|
|
US7625564B2
(en)
|
2006-01-27 |
2009-12-01 |
Novagen Holding Corporation |
Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
|
|
WO2007097923A2
(en)
|
2006-02-20 |
2007-08-30 |
Phylogica Limited |
Method of constructing and screening libraries of peptide structures
|
|
US8784833B2
(en)
|
2006-06-27 |
2014-07-22 |
Saint Louis University |
Prenatal enzyme replacement therapy for hypophosphatasia
|
|
WO2008053362A2
(en)
|
2006-06-30 |
2008-05-08 |
Interface Biologics, Inc. |
Bioresponsive polymers
|
|
US7825092B2
(en)
|
2006-08-08 |
2010-11-02 |
University Of South Florida |
Dendroaspis natriuretic peptide for treatment of cancer
|
|
TW200817431A
(en)
|
2006-08-08 |
2008-04-16 |
Mayo Foundation |
Diuretic and natriuretic polypeptides
|
|
WO2008030558A2
(en)
|
2006-09-08 |
2008-03-13 |
Ambrx, Inc. |
Modified human plasma polypeptide or fc scaffolds and their uses
|
|
BRPI0716228A2
(pt)
|
2006-09-08 |
2013-10-15 |
Mayo Foundation |
Polipeptídeos aquaréticos e natriuréticos carecendo de atividade vasodilatadora
|
|
WO2008088422A2
(en)
|
2006-10-25 |
2008-07-24 |
Amgen Inc. |
Toxin peptide therapeutic agents
|
|
US20100168443A1
(en)
|
2006-11-02 |
2010-07-01 |
University Of Virginia Patent Foundation |
Ethoid-Containing Compounds, Methods for Preparing Ethoid-Containing Compounds, and Methods of Use
|
|
CA2669914C
(en)
|
2006-11-16 |
2017-11-07 |
Kai Pharmaceuticals, Inc. |
Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders
|
|
US20080181903A1
(en)
|
2006-12-21 |
2008-07-31 |
Pdl Biopharma, Inc. |
Conjugate of natriuretic peptide and antibody constant region
|
|
JP5250568B2
(ja)
|
2007-03-12 |
2013-07-31 |
ビオメディカ・メディツィーンプロドゥクテ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフト |
敗血症の合併症の検査
|
|
EP1985697A1
(en)
|
2007-04-27 |
2008-10-29 |
AM-Pharma B.V. |
Modified phosphatases
|
|
KR20080098216A
(ko)
|
2007-05-04 |
2008-11-07 |
한미약품 주식회사 |
캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체
|
|
PL2158319T4
(pl)
|
2007-05-11 |
2016-04-29 |
Alexion Pharma Inc |
Fosfataza alkaliczna kierowana do kości, zestawy i zastosowanie
|
|
BRPI0811857A2
(pt)
|
2007-05-14 |
2014-10-21 |
Biogen Idec Inc |
Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados.
|
|
EP2162464A1
(en)
|
2007-06-06 |
2010-03-17 |
Boehringer Ingelheim International GmbH |
Natriuretic fusion proteins
|
|
WO2008154543A2
(en)
|
2007-06-11 |
2008-12-18 |
Abbott Biotechnology Ltd. |
Methods for treating juvenile idiopathic arthritis
|
|
US20110077383A1
(en)
|
2007-07-03 |
2011-03-31 |
Medimmune, Llc |
Hinge domain engineering
|
|
CN102066421A
(zh)
|
2007-07-06 |
2011-05-18 |
瑟瑞技术公司 |
α-促黑激素（α-MSH）和心房利尿钠蛋白（ANP）的双功能融合蛋白以及在高血压和急性肾损伤中的用途
|
|
PT2765139T
(pt)
|
2007-07-20 |
2017-07-14 |
Mayo Foundation |
Polipéptidos natriuréticos
|
|
EP2190466A4
(en)
|
2007-08-10 |
2011-12-21 |
Burnham Inst Medical Research |
Tissue-specific alkaline phosphatase (TNAP) activators and their use
|
|
BRPI0815416A2
(pt)
|
2007-08-15 |
2014-10-21 |
Amunix Inc |
Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos
|
|
WO2009040006A1
(en)
|
2007-09-11 |
2009-04-02 |
Mondobiotech Laboratories Ag |
Spantide for therapeutic uses
|
|
JP5395794B2
(ja)
|
2007-09-11 |
2014-01-22 |
モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト |
治療剤としてのガラニンペプチドの使用
|
|
US8293711B2
(en)
|
2007-09-11 |
2012-10-23 |
Pharis Biotech Gmbh |
Use of natriuretic peptides for treating angioedema syndromes
|
|
KR20100056517A
(ko)
|
2007-09-11 |
2010-05-27 |
몬도바이오테크 래보래토리즈 아게 |
치료제로서의 펩티드의 용도
|
|
KR20100057050A
(ko)
|
2007-09-11 |
2010-05-28 |
몬도바이오테크 래보래토리즈 아게 |
치료제로서의 데슬로렐린 및 마스토파란의 용도
|
|
KR20100057641A
(ko)
|
2007-09-11 |
2010-05-31 |
몬도바이오테크 래보래토리즈 아게 |
인터메딘 ４７ 및 ５３ 펩티드의 치료적 용도
|
|
WO2009036448A2
(en)
|
2007-09-15 |
2009-03-19 |
Mayo Foundation For Medical Education And Research |
Natriuretic peptide receptor-c agonists
|
|
AR069409A1
(es)
|
2007-11-21 |
2010-01-20 |
Biomarin Pharm Inc |
Variantes de peptidos natriureticos de tipo c
|
|
WO2009086126A2
(en)
|
2007-12-21 |
2009-07-09 |
Mayo Foundation For Medical Education And Research |
Natriuretic polypeptides
|
|
EP2080812A1
(en)
|
2008-01-18 |
2009-07-22 |
Transmedi SA |
Compositions and methods of detecting post-stop peptides
|
|
BRPI0904622A2
(pt)
|
2008-05-23 |
2016-06-21 |
Asubio Pharma Co Ltd |
peptídeo com ação de prolongar a meia-vida de um peptídeo de interesse no plasma
|
|
CA2727085A1
(en)
|
2008-06-06 |
2009-12-10 |
Mayo Foundation For Medical Education And Research |
Chimeric natriuretic polypeptides and methods for inhibiting cardiac remodeling
|
|
WO2009156481A1
(en)
|
2008-06-25 |
2009-12-30 |
Ascendis Pharma As |
Pegylated bnp
|
|
US20100008918A1
(en)
|
2008-06-26 |
2010-01-14 |
Acceleron Pharma Inc. |
Methods for dosing an actriib antagonist and monitoring of treated patients
|
|
DK2307447T3
(da)
|
2008-07-02 |
2016-06-20 |
Mayo Foundation |
Natriuretiske polypeptider med unikke farmakologiske profiler
|
|
KR101200659B1
(ko)
|
2008-07-23 |
2012-11-12 |
한미사이언스 주식회사 |
세 말단 반응기를 갖는 비펩타이드성 중합체를 이용한 생리활성 폴리펩타이드 약물 결합체
|
|
US20100093678A1
(en)
|
2008-10-10 |
2010-04-15 |
The University Of Georgia Research Foundation, Inc |
Compositions and methods of the treatment of obesity and osteoporosis
|
|
WO2010048308A2
(en)
|
2008-10-24 |
2010-04-29 |
Deborah Dickey |
Natriuretic polypeptides
|
|
WO2010078325A2
(en)
|
2008-12-29 |
2010-07-08 |
Mayo Foundation For Medical Education And Research |
Natriuretic polypeptides for reducing or preventing restenosis
|
|
TW201031752A
(en)
|
2009-01-19 |
2010-09-01 |
Hanmi Pharm Ind Co Ltd |
Method for producing physiologically active protein or peptide using immunoglobulin fragment
|
|
EP2413969A4
(en)
|
2009-03-30 |
2012-09-05 |
Boehringer Ingelheim Int |
FUSION PROTEINS WITH DOG FC ELEMENTS
|
|
US20120053123A1
(en)
|
2009-05-05 |
2012-03-01 |
Mayo Foundation For Medical Education And Research |
Natriuretic polypeptides having mutations within their disulfide rings
|
|
HRP20161739T1
(hr)
|
2009-05-20 |
2017-03-10 |
Biomarin Pharmaceutical Inc. |
VARIJANTE NATRIURETIČNOG PEPTIDA C-tipa
|
|
AU2011245005A1
(en)
*
|
2010-04-30 |
2012-11-22 |
Alexion Pharma Holding |
Methods, compositions, and kits for the treatment of matrix mineralization disorders
|
|
CA2823066A1
(en)
|
2010-12-27 |
2012-07-05 |
Alexion Pharma International Sarl |
Compositions comprising natriuretic peptides and methods of use thereof
|
|
SG11201401605QA
(en)
|
2011-10-19 |
2014-09-26 |
Alexion Pharma Holding |
Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
|
|
CN109985228A
(zh)
|
2011-11-10 |
2019-07-09 |
凯伊药品公司 |
拟钙剂及其使用方法
|
|
US10052366B2
(en)
*
|
2012-05-21 |
2018-08-21 |
Alexion Pharmaceuticsl, Inc. |
Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
|
|
WO2014016585A1
(en)
|
2012-07-25 |
2014-01-30 |
Psioxus Therapeutics Limited |
Use of s-pindolol for treating cachexia and sarcopenia
|
|
WO2014186809A2
(en)
|
2013-05-17 |
2014-11-20 |
The Translational Genomics Research Institute |
A genetic test to predict patient response to bone morphogenetic protein in arthrodesis
|
|
CA2936829C
(en)
|
2014-01-24 |
2024-05-28 |
Am-Pharma B.V. |
Downstream processing of an alkaline phosphatase
|
|
LT3151859T
(lt)
|
2014-06-09 |
2021-03-25 |
Ultragenyx Pharmaceutical Inc. |
Veiksminga ir efektyvi serumo fosfatų kontrolė optimaliam kaulų formavimosi užtikrinimui
|
|
US10822596B2
(en)
|
2014-07-11 |
2020-11-03 |
Alexion Pharmaceuticals, Inc. |
Compositions and methods for treating craniosynostosis
|
|
CA2967851C
(en)
|
2014-12-05 |
2024-02-27 |
Alexion Pharmaceuticals, Inc. |
Treating seizure with recombinant alkaline phosphatase
|
|
US10603361B2
(en)
|
2015-01-28 |
2020-03-31 |
Alexion Pharmaceuticals, Inc. |
Methods of treating a subject with an alkaline phosphatase deficiency
|
|
KR101867134B1
(ko)
|
2015-03-23 |
2018-06-12 |
한양대학교 산학협력단 |
포유류 세포를 이용하여 목적 물질을 고효율로 생산하기 위한 세포 배양 배지, 이를 이용한 세포 배양 방법 및 목적 물질의 생산 방법
|
|
RU2745528C2
(ru)
|
2015-08-17 |
2021-03-26 |
Алексион Фармасьютикалз, Инк. |
Производство щелочных фосфатаз
|
|
WO2017058822A1
(en)
|
2015-09-28 |
2017-04-06 |
Alexion Pharmaceuticals, Inc. |
Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
|
|
WO2017074466A1
(en)
|
2015-10-30 |
2017-05-04 |
Alexion Pharmaceuticals, Inc. |
Methods for treating craniosynostosis in a patient
|
|
EP3426286A4
(en)
|
2016-03-08 |
2019-12-04 |
Alexion Pharmaceuticals, Inc. |
PROCESS FOR TREATING HYPOPHOSPHATASIA IN CHILDREN
|
|
JP7613826B2
(ja)
|
2016-04-01 |
2025-01-15 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
アルカリホスファターゼによって筋力低下を治療すること
|
|
WO2017171871A1
(en)
|
2016-04-01 |
2017-10-05 |
Alexion Pharmaceuticals, Inc. |
Methods for treating hypophosphatasia in adolescents and adults
|
|
EP3436020A4
(en)
|
2016-04-01 |
2019-12-25 |
Alexion Pharmaceuticals, Inc. |
METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS
|
|
US10988744B2
(en)
|
2016-06-06 |
2021-04-27 |
Alexion Pharmaceuticals, Inc. |
Method of producing alkaline phosphatase
|
|
WO2018004517A1
(en)
|
2016-06-27 |
2018-01-04 |
Alexion Pharmaceuticals, Inc. |
Methods for treating hypophosphatasia in children and adolescents
|
|
EP3500289B1
(en)
|
2016-08-18 |
2024-10-09 |
Alexion Pharmaceuticals, Inc. |
Asfotase alfa for use in treating tracheobronchomalacia
|
|
WO2018164995A1
(en)
|
2017-03-09 |
2018-09-13 |
Alexion Pharmaceuticals, Inc . |
Glycoprotein manufacturing process
|